Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024
Company affirms projection of operational funds into early 2026
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.